Could  ||| S:0 E:6 ||| MD
be  ||| S:6 E:9 ||| VB
a  ||| S:9 E:11 ||| DT
link  ||| S:11 E:16 ||| NN
between  ||| S:16 E:24 ||| IN
non  ||| S:24 E:28 ||| JJ
atopic  ||| S:28 E:35 ||| JJ
asthma  ||| S:35 E:42 ||| NN
and  ||| S:42 E:46 ||| CC
HP  ||| S:46 E:49 ||| NNP
infection ||| S:49 E:58 ||| NN
?  ||| S:58 E:60 ||| .
A  ||| S:60 E:62 ||| DT
potential  ||| S:62 E:72 ||| JJ
role  ||| S:72 E:77 ||| NN
of  ||| S:77 E:80 ||| IN
Helicobater  ||| S:80 E:92 ||| NNP
Pylori  ||| S:92 E:99 ||| NNP
( ||| S:99 E:100 ||| -LRB-
HP ||| S:100 E:102 ||| NNP
)  ||| S:102 E:104 ||| -RRB-
infection  ||| S:104 E:114 ||| NN
in  ||| S:114 E:117 ||| IN
several  ||| S:117 E:125 ||| JJ
extra-intestinal  ||| S:125 E:142 ||| JJ
pathologies  ||| S:142 E:154 ||| NN
has  ||| S:154 E:158 ||| VBZ
been  ||| S:158 E:163 ||| VBN
recently  ||| S:163 E:172 ||| RB
suggested ||| S:172 E:181 ||| VBD
.  ||| S:181 E:183 ||| .
The  ||| S:183 E:187 ||| DT
aim  ||| S:187 E:191 ||| NN
of  ||| S:191 E:194 ||| IN
our  ||| S:194 E:198 ||| PRP$
study  ||| S:198 E:204 ||| NN
was  ||| S:204 E:208 ||| VBD
to  ||| S:208 E:211 ||| TO
assess  ||| S:211 E:218 ||| VB
the  ||| S:218 E:222 ||| DT
role  ||| S:222 E:227 ||| NN
of  ||| S:227 E:230 ||| IN
serology  ||| S:230 E:239 ||| JJ
positive  ||| S:239 E:248 ||| JJ
for  ||| S:248 E:252 ||| IN
HP  ||| S:252 E:255 ||| NNP
in  ||| S:255 E:258 ||| IN
atopic  ||| S:258 E:265 ||| NN
and  ||| S:265 E:269 ||| CC
non  ||| S:269 E:273 ||| JJ
atopic  ||| S:273 E:280 ||| JJ
infants  ||| S:280 E:288 ||| NNS
and  ||| S:288 E:292 ||| CC
children  ||| S:292 E:301 ||| NNS
affected  ||| S:301 E:310 ||| VBN
by  ||| S:310 E:313 ||| IN
atopic  ||| S:313 E:320 ||| JJ
dermatitis ||| S:320 E:330 ||| NN
,  ||| S:330 E:332 ||| ,
urticaria ||| S:332 E:341 ||| NN
,  ||| S:341 E:343 ||| ,
rhinitis  ||| S:343 E:352 ||| NN
and  ||| S:352 E:356 ||| CC
asthma ||| S:356 E:362 ||| NN
.  ||| S:362 E:364 ||| .
We  ||| S:364 E:367 ||| PRP
included  ||| S:367 E:376 ||| VBD
615  ||| S:376 E:380 ||| CD
children  ||| S:380 E:389 ||| NNS
affected  ||| S:389 E:398 ||| VBN
by  ||| S:398 E:401 ||| IN
atopic  ||| S:401 E:408 ||| JJ
diseases ||| S:408 E:416 ||| NNS
.  ||| S:416 E:418 ||| .
According  ||| S:418 E:428 ||| VBG
to  ||| S:428 E:431 ||| TO
prick  ||| S:431 E:437 ||| VB
test  ||| S:437 E:442 ||| NN
positivity  ||| S:442 E:453 ||| NNS
and  ||| S:453 E:457 ||| CC
age ||| S:457 E:460 ||| NN
,  ||| S:460 E:462 ||| ,
we  ||| S:462 E:465 ||| PRP
divided  ||| S:465 E:473 ||| VBD
the  ||| S:473 E:477 ||| DT
patients  ||| S:477 E:486 ||| NNS
into  ||| S:486 E:491 ||| IN
two  ||| S:491 E:495 ||| CD
groups ||| S:495 E:501 ||| NNS
:  ||| S:501 E:503 ||| :
atopic  ||| S:503 E:510 ||| NNS
or  ||| S:510 E:513 ||| CC
non-atopic  ||| S:513 E:524 ||| JJ
patients  ||| S:524 E:533 ||| NNS
and  ||| S:533 E:537 ||| CC
infants  ||| S:537 E:545 ||| NNS
( ||| S:545 E:546 ||| -LRB-
0-2  ||| S:546 E:550 ||| CD
years ||| S:550 E:555 ||| NNS
)  ||| S:555 E:557 ||| -RRB-
or  ||| S:557 E:560 ||| CC
children  ||| S:560 E:569 ||| NNS
( ||| S:569 E:570 ||| -LRB-
2-12  ||| S:570 E:575 ||| CD
years ||| S:575 E:580 ||| NNS
) ||| S:580 E:581 ||| -RRB-
.  ||| S:581 E:583 ||| .
The  ||| S:583 E:587 ||| DT
serum  ||| S:587 E:593 ||| JJ
levels  ||| S:593 E:600 ||| NNS
of  ||| S:600 E:603 ||| IN
antibodies  ||| S:603 E:614 ||| NNS
for  ||| S:614 E:618 ||| IN
H.  ||| S:618 E:621 ||| NNP
pylori  ||| S:621 E:628 ||| FW
immunoglobulin  ||| S:628 E:643 ||| FW
G  ||| S:643 E:645 ||| NNP
were  ||| S:645 E:650 ||| VBD
measured  ||| S:650 E:659 ||| VBN
by  ||| S:659 E:662 ||| IN
using  ||| S:662 E:668 ||| VBG
an  ||| S:668 E:671 ||| DT
ELISA  ||| S:671 E:677 ||| NNP
test ||| S:677 E:681 ||| NN
.  ||| S:681 E:683 ||| .
We  ||| S:683 E:686 ||| PRP
found  ||| S:686 E:692 ||| VBD
a  ||| S:692 E:694 ||| DT
not  ||| S:694 E:698 ||| RB
significant  ||| S:698 E:710 ||| JJ
difference  ||| S:710 E:721 ||| NN
between  ||| S:721 E:729 ||| IN
group  ||| S:729 E:735 ||| NN
1  ||| S:735 E:737 ||| CD
and  ||| S:737 E:741 ||| CC
group  ||| S:741 E:747 ||| NN
2  ||| S:747 E:749 ||| CD
about  ||| S:749 E:755 ||| IN
atopy ||| S:755 E:760 ||| NN
.  ||| S:760 E:762 ||| .
There  ||| S:762 E:768 ||| EX
was  ||| S:768 E:772 ||| VBD
a  ||| S:772 E:774 ||| DT
significant  ||| S:774 E:786 ||| JJ
higher  ||| S:786 E:793 ||| JJR
frequency  ||| S:793 E:803 ||| NN
of  ||| S:803 E:806 ||| IN
HP  ||| S:806 E:809 ||| NNP
positive  ||| S:809 E:818 ||| JJ
serology  ||| S:818 E:827 ||| NN
in  ||| S:827 E:830 ||| IN
older  ||| S:830 E:836 ||| JJR
children ||| S:836 E:844 ||| NNS
.  ||| S:844 E:846 ||| .
As  ||| S:846 E:849 ||| RB
for  ||| S:849 E:853 ||| IN
infants ||| S:853 E:860 ||| NNS
,  ||| S:860 E:862 ||| ,
a  ||| S:862 E:864 ||| DT
higher  ||| S:864 E:871 ||| JJR
significant  ||| S:871 E:883 ||| JJ
prevalence  ||| S:883 E:894 ||| NN
of  ||| S:894 E:897 ||| IN
HP  ||| S:897 E:900 ||| NNP
positive  ||| S:900 E:909 ||| JJ
serology  ||| S:909 E:918 ||| NN
was  ||| S:918 E:922 ||| VBD
found  ||| S:922 E:928 ||| VBN
in  ||| S:928 E:931 ||| IN
non-atopic  ||| S:931 E:942 ||| JJ
patients ||| S:942 E:950 ||| NNS
.  ||| S:950 E:952 ||| .
HP  ||| S:952 E:955 ||| NNP
positive  ||| S:955 E:964 ||| JJ
serology  ||| S:964 E:973 ||| NN
was  ||| S:973 E:977 ||| VBD
significantly  ||| S:977 E:991 ||| RB
higher  ||| S:991 E:998 ||| RBR
only  ||| S:998 E:1003 ||| RB
in  ||| S:1003 E:1006 ||| IN
non-atopic  ||| S:1006 E:1017 ||| JJ
infants  ||| S:1017 E:1025 ||| NNS
affected  ||| S:1025 E:1034 ||| VBN
by  ||| S:1034 E:1037 ||| IN
atopic  ||| S:1037 E:1044 ||| JJ
dermatitis  ||| S:1044 E:1055 ||| NN
and  ||| S:1055 E:1059 ||| CC
urticaria  ||| S:1059 E:1069 ||| NN
than  ||| S:1069 E:1074 ||| IN
in  ||| S:1074 E:1077 ||| IN
atopic ||| S:1077 E:1083 ||| NN
.  ||| S:1083 E:1085 ||| .
In  ||| S:1085 E:1088 ||| IN
group  ||| S:1088 E:1094 ||| NN
2 ||| S:1094 E:1095 ||| CD
,  ||| S:1095 E:1097 ||| ,
non  ||| S:1097 E:1101 ||| JJ
atopic  ||| S:1101 E:1108 ||| JJ
children  ||| S:1108 E:1117 ||| NNS
shown  ||| S:1117 E:1123 ||| VBN
a  ||| S:1123 E:1125 ||| DT
significant  ||| S:1125 E:1137 ||| JJ
increase  ||| S:1137 E:1146 ||| NN
in  ||| S:1146 E:1149 ||| IN
the  ||| S:1149 E:1153 ||| DT
prevalence  ||| S:1153 E:1164 ||| NN
of  ||| S:1164 E:1167 ||| IN
HP  ||| S:1167 E:1170 ||| NNP
serum  ||| S:1170 E:1176 ||| VBD
positivity  ||| S:1176 E:1187 ||| VBN
than  ||| S:1187 E:1192 ||| IN
atopic  ||| S:1192 E:1199 ||| JJ
children ||| S:1199 E:1207 ||| NNS
.  ||| S:1207 E:1209 ||| .
As  ||| S:1209 E:1212 ||| RB
for  ||| S:1212 E:1216 ||| IN
asthma ||| S:1216 E:1222 ||| NN
,  ||| S:1222 E:1224 ||| ,
there  ||| S:1224 E:1230 ||| EX
was  ||| S:1230 E:1234 ||| VBD
an  ||| S:1234 E:1237 ||| DT
higher  ||| S:1237 E:1244 ||| JJR
prevalence  ||| S:1244 E:1255 ||| NN
of  ||| S:1255 E:1258 ||| IN
HP  ||| S:1258 E:1261 ||| NNP
serology  ||| S:1261 E:1270 ||| FW
positive  ||| S:1270 E:1279 ||| FW
in  ||| S:1279 E:1282 ||| FW
non  ||| S:1282 E:1286 ||| FW
atopic  ||| S:1286 E:1293 ||| FW
asthmatic  ||| S:1293 E:1303 ||| FW
children  ||| S:1303 E:1312 ||| NNS
group  ||| S:1312 E:1318 ||| NN
than  ||| S:1318 E:1323 ||| IN
in  ||| S:1323 E:1326 ||| IN
atopic  ||| S:1326 E:1333 ||| JJ
asthmatics ||| S:1333 E:1343 ||| NN
.  ||| S:1343 E:1345 ||| .
On  ||| S:1345 E:1348 ||| IN
the  ||| S:1348 E:1352 ||| DT
contrary ||| S:1352 E:1360 ||| NN
,  ||| S:1360 E:1362 ||| ,
the  ||| S:1362 E:1366 ||| DT
prevalence  ||| S:1366 E:1377 ||| NN
of  ||| S:1377 E:1380 ||| IN
positive  ||| S:1380 E:1389 ||| JJ
HP  ||| S:1389 E:1392 ||| NNP
serology  ||| S:1392 E:1401 ||| NN
was  ||| S:1401 E:1405 ||| VBD
not  ||| S:1405 E:1409 ||| RB
significantly  ||| S:1409 E:1423 ||| RB
different  ||| S:1423 E:1433 ||| JJ
between  ||| S:1433 E:1441 ||| IN
atopic  ||| S:1441 E:1448 ||| NN
and  ||| S:1448 E:1452 ||| CC
non  ||| S:1452 E:1456 ||| JJ
atopic  ||| S:1456 E:1463 ||| JJ
children  ||| S:1463 E:1472 ||| NNS
affected  ||| S:1472 E:1481 ||| VBN
by  ||| S:1481 E:1484 ||| IN
dermatitis ||| S:1484 E:1494 ||| NN
,  ||| S:1494 E:1496 ||| ,
urticaria ||| S:1496 E:1505 ||| NN
,  ||| S:1505 E:1507 ||| ,
and  ||| S:1507 E:1511 ||| CC
rhinitis ||| S:1511 E:1519 ||| NN
.  ||| S:1519 E:1521 ||| .
The  ||| S:1521 E:1525 ||| DT
present  ||| S:1525 E:1533 ||| JJ
data  ||| S:1533 E:1538 ||| NNS
confirm  ||| S:1538 E:1546 ||| VBP
an  ||| S:1546 E:1549 ||| DT
inverse  ||| S:1549 E:1557 ||| JJ
association  ||| S:1557 E:1569 ||| NN
between  ||| S:1569 E:1577 ||| IN
HP  ||| S:1577 E:1580 ||| NNP
positive  ||| S:1580 E:1589 ||| JJ
serology  ||| S:1589 E:1598 ||| NN
and  ||| S:1598 E:1602 ||| CC
atopy  ||| S:1602 E:1608 ||| NN
in  ||| S:1608 E:1611 ||| IN
both  ||| S:1611 E:1616 ||| DT
groups ||| S:1616 E:1622 ||| NNS
.  ||| S:1622 E:1624 ||| .
However ||| S:1624 E:1631 ||| RB
,  ||| S:1631 E:1633 ||| ,
the  ||| S:1633 E:1637 ||| DT
higher  ||| S:1637 E:1644 ||| JJR
prevalence  ||| S:1644 E:1655 ||| NN
of  ||| S:1655 E:1658 ||| IN
positive  ||| S:1658 E:1667 ||| JJ
HP  ||| S:1667 E:1670 ||| NNP
serology  ||| S:1670 E:1679 ||| NN
was  ||| S:1679 E:1683 ||| VBD
observed  ||| S:1683 E:1692 ||| VBN
in  ||| S:1692 E:1695 ||| IN
non  ||| S:1695 E:1699 ||| JJ
atopic  ||| S:1699 E:1706 ||| JJ
asthmatics  ||| S:1706 E:1717 ||| JJ
children  ||| S:1717 E:1726 ||| NNS
than  ||| S:1726 E:1731 ||| IN
in  ||| S:1731 E:1734 ||| IN
atopic  ||| S:1734 E:1741 ||| JJ
asthmatics ||| S:1741 E:1751 ||| NN
.  ||| S:1751 E:1753 ||| .
We  ||| S:1753 E:1756 ||| PRP
could  ||| S:1756 E:1762 ||| MD
speculate  ||| S:1762 E:1772 ||| VB
that  ||| S:1772 E:1777 ||| IN
HP  ||| S:1777 E:1780 ||| NNP
infection  ||| S:1780 E:1790 ||| NN
can  ||| S:1790 E:1794 ||| MD
favour  ||| S:1794 E:1801 ||| VB
non-atopic  ||| S:1801 E:1812 ||| JJ
asthma  ||| S:1812 E:1819 ||| NN
onset ||| S:1819 E:1824 ||| NN
.  ||| S:1824 E:1826 ||| .
